The San Diego, CA-based biotech currently markets
four molecular tests that screen for the risk of genetic diseases,
chromosomal disorders and hereditary cancer risk. It is also developing
ingestible devices and drug/device combinations aimed at precision
diagnostic sampling and drug delivery solutions.
2019 Financials: Revenues:
$144.0M (+12.5%); Operating Expenses: $183.6M (+22.3%); Net Loss:
($228.8M) (-77.2%); Cash Flow Ops: ($106.1M) (-63.0%).
https://seekingalpha.com/news/3578302-progenity-on-deck-for-ipo
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.